术前FNA分子检测发现的PTEN改变甲状腺结节恶性风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入2020至2025年间报道术前FNA分子检测发现PTEN改变且经手术组织病理学验证的研究。三项队列共87个切除的PTEN改变结节,其中28例为浸润性恶性肿瘤,汇总恶性风险为32.4%(95%CI 23.4-42.9;I2=0%)。将NIFTP计为事件后汇总恶性风险升至37.7%(95%CI 23.9-53.9)。结论认为术前PTEN改变提示中等恶性风险,受手术选择路径和PTEN改变定义方式影响。
要点
- PTEN改变甲状腺结节汇总浸润性恶性风险32.4%(95%CI 23.4-42.9)。
- 将NIFTP计为事件后汇总恶性风险升至37.7%(95%CI 23.9-53.9)。
- PTEN改变应作为中等风险分子发现沟通,支持病理-影像-分子整合决策。
核心结论
- 术前检测到的PTEN改变在手术随访队列中 confer 中等恶性风险(约32%),但受手术选择路径和PTEN改变操作化定义(序列变异vs蛋白丢失)调节。
- PTEN改变的术前结果应作为中等风险分子发现沟通,常映射滤泡/嗜酸细胞肿瘤,但也包括分化癌和罕见高级别病变。
研究设计与样本
- 系统综述与荟萃分析,检索2020-2025年间报道术前FNA分子检测发现PTEN改变并经手术组织病理学验证的研究。
- 主要荟萃分析纳入以Bethesda III/IV为主、PTEN改变结节接受手术的队列;采用随机效应模型汇总浸润性恶性风险,并进行将NIFTP计为事件的敏感性分析。
主要发现
- 三项队列共87个切除的PTEN改变结节,其中28例为浸润性恶性肿瘤。
- 浸润性恶性肿瘤汇总恶性风险为32.4%(95%CI 23.4-42.9;I2=0%)。
- 将NIFTP计为事件后汇总恶性风险升至37.7%(95%CI 23.9-53.9)。
- 恶性结局包括滤泡性甲状腺癌、甲状腺乳头状癌(含变异型)及罕见低分化或未分化甲状腺癌。
临床怎么用
- PTEN改变的术前FNA结果应作为中等风险分子发现进行沟通,支持病理-影像-分子整合决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Phosphatase and tensin homolog (PTEN) alterations are increasingly encountered on molecular testing of thyroid fine-needle aspiration (FNA) specimens in Bethesda III/IV nodules. Unlike high-specificity alterations (e.g., BRAF V600E), PTEN alterations can map to a broad morphologic spectrum and are influenced by the diagnostic pathway determining which nodules proceed to surgery. We performed a systematic review and meta-analysis to define risk of malignancy (ROM) for PTEN-altered thyroid nodules detected preoperatively. METHODS: Studies (2020-2025) reporting PTEN alterations detected preoperatively on FNA-based testing with surgical histopathology were reviewed. The primary meta-analysis included Bethesda III/IV-predominant cohorts with PTEN-altered nodules undergoing surgery. We pooled invasive malignancy ROM using random-effects meta-analysis and performed a sensitivity analysis counting noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) as an event. RESULTS: Three cohorts comprised 87 resected PTEN-altered nodules with 28 invasive malignancies. Pooled ROM for invasive malignancy was 32.4% (95% confidence interval (CI) 23.4-42.9; I2 = 0%). Malignant outcomes included follicular thyroid carcinoma, papillary thyroid carcinoma (including variants), and rare poorly differentiated or anaplastic thyroid carcinoma. Counting NIFTP as an event increased pooled ROM to 37.7% (95% CI 23.9-53.9). CONCLUSIONS: PTEN alterations detected preoperatively confer an intermediate ROM (∼32%) in surgically followed cohorts, but ROM is modulated by pathway-related selection for surgery and by how PTEN alteration is operationalized (sequence variant vs protein loss). A PTEN-altered preoperative result should be communicated as a moderate-risk molecular finding that frequently maps to follicular/oncocytic neoplasia yet includes differentiated carcinomas and rare high-grade disease, supporting integrated pathology-radiology-molecular decision-making.
引用
- Straccia P, Fiorentino V, Urtueta BP, et al. Risk of malignancy in PTEN-altered thyroid nodules detected on preoperative FNA molecular testing: a systematic review and meta-analysis. Hum Pathol. 2026. PMID: 41865773. doi:10.1016/j.humpath.2026.106104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。